Initial loading (400 μg twice daily) versus static (400 μg nocte) dose budesonide for asthma management

International Journal of Clinical Practice

Volumn 52, Issue 6, 1998, Pages

  Campbell, L M ^a   Gooding, T N ^b   Aitchison, W R C ^c   Smith, N ^d   Powell, J A ^d  

^a Southbank Surgery   (United Kingdom)

^b Atherstone Surgery   (United Kingdom)

^c The Surgery   (United Kingdom)

^d Astra Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE;

ADULT; AROUSAL; ARTICLE; ASTHMA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SLEEP DISORDER;

ADULT; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 3543115445     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London, in association with the General Practitioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. The British guidelines on asthma management 1995 review and position statement. Thorax 1997; 52(suppl 1): S2-S21.
2. Selroos O, Backman R, Forsen K-O et al. The effect of inhaled corticosteroids in asthma is related to the duration of pretreatment symptoms. Am J Resp Crit Care Med 1994; 149: A211.
3. Selroos O, Backman R, Forsen K-O et al. When to start treatment of asthma with inhaled steroids? Eur Resp J 1994; 7(suppl 18): 151S.
4. Konig P. Inhaled corticosteroids, their present and future role in the management of asthma. J Allergy Clin Immunol 1988; 82: 297-306.
5. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbohaler® is twice that from a pressurised meter-dose inhaler pMDI. Eur Resp J 1994; 7: 1839-1844.
6. Campbell LM, Watson DG, Venables TL et al. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 1991; 2: 111-122.
7. Campbell LM, Gunn SD, Sweeney D et al. Once daily budesonide: effective control of moderately severe asthma with 800 μg once daily inhaled via Turbohaler when compared with 400 μg twice daily. Eur J Clin Res 1995; 7: 1-14.
8. Nunn AJ, Gregg I. New regression equations for predicting peak flow in adults. BMJ 1989; 298: 1068-1070.
9. Pirozynski M, Kulaga Z, Karlstrom R. Pulmicort® (budesonide) Turbohaler® in mild to moderate asthma: comparison of initial high dose, constant low dose and placebo. Am J Resp Crit Care Med 1996; 153(4 Pt 2): A343.
10. Rees TP, Lennox B, Timney AP et al. Comparison of increasing the dose of budesonide to 800 μg/day with a maintained dose of 400 μg/day in mild-to-moderate asthmatic patients. Eur J Clin Res 1993; 4: 67-77.
11. Weiss KB, Wagener DK. Changing patterns of asthma mortality: identifying target populations at high risk. JAMA 1990; 264: 1683-1687.
12. Sheffer AL, Bousquet J, Bosse WW et al. International consensus report on the diagnosis and treatment of asthma. Eur Resp J 1992; 5: 601-641.
13. Miyamoto T, Takahashi T, Nakajima S et al. A double-blind, placebo controlled, parallel group, mulicentre dose response study of Pulmicort® (budesonide) Turbohaler® in Japanese patients with mild or moderate asthma. Am J Crit Care Med 1996; 153(4 Pt 2): A339.